Ado-trastuzumab emtansine (T-DM1) was the first HER2-targeted antibody-drug conjugate to get the approval of the Food and Drug Administration (FDA) in 2013 for the treatment of metastatic HER2-positive BC. This evidence concerns the gene ERBB2 and breast cancer.